File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels

TitleOral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels
Authors
KeywordsOxidative damage
Type 2 diabetes
Vascular function
Zinc
Issue Date2011
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis
Citation
Atherosclerosis, 2011, v. 219 n. 1, p. 231-239 How to Cite?
AbstractObjective: There is considerable controversy about what constitutes optimal zinc intakes in patients with type 2 diabetes mellitus. Several studies suggest that higher zinc intakes improve vascular function and decrease oxidative damage. We aimed to assess the effects of zinc supplementation using a range of reliable biomarkers of oxidative damage and vascular function in patients with type 2 diabetes. Methods: Forty male type 2 diabetic patients were supplemented either with 240mg/day of zinc as zinc gluconate (n=20) or with placebo (n=20) for 3 months. Blood and spot urine samples were taken at baseline, days 3 and 7, months 1, 2 and 3 during supplementation and 1 month after cessation. Serum zinc, reliable biomarkers of oxidative damage (F 2-isoprostanes, neuroprostanes, cholesterol oxidation products, allantoin) as well as hydroxyeicosatetraenoic acid products and vascular-related indices (augmentation index, pulse wave velocity and aortic pressure) were measured. Results: Despite significantly higher levels of serum zinc in the treatment group, markers of oxidative damage, levels of hydroxyeicosatetraenoic acid products and vascular indices were unchanged by zinc supplementation during the four-month study period. Conclusion: Improving the zinc status in patients with type 2 diabetes with normal zinc levels did not have any impact on oxidative damage and vascular function, and such supplementation may not be generally beneficial in these individuals. © 2011 Elsevier Ireland Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/143937
ISSN
2015 Impact Factor: 3.942
2015 SCImago Journal Rankings: 1.819
ISI Accession Number ID
Funding AgencyGrant Number
Biomedical Research Council03/1/21/18/213
National Medical Research Council, SingaporeNMRC/1157/2008
Funding Information:

Funding: Supported by the Biomedical Research Council (Grant 03/1/21/18/213) and National Medical Research Council (Grant NMRC/1157/2008), Singapore.

References

 

DC FieldValueLanguage
dc.contributor.authorSeet, RCSen_HK
dc.contributor.authorLee, CYJen_HK
dc.contributor.authorLim, ECHen_HK
dc.contributor.authorQuek, AMLen_HK
dc.contributor.authorHuang, Hen_HK
dc.contributor.authorHuang, SHen_HK
dc.contributor.authorLooi, WFen_HK
dc.contributor.authorLong, LHen_HK
dc.contributor.authorHalliwell, Ben_HK
dc.date.accessioned2011-12-21T08:59:39Z-
dc.date.available2011-12-21T08:59:39Z-
dc.date.issued2011en_HK
dc.identifier.citationAtherosclerosis, 2011, v. 219 n. 1, p. 231-239en_HK
dc.identifier.issn0021-9150en_HK
dc.identifier.urihttp://hdl.handle.net/10722/143937-
dc.description.abstractObjective: There is considerable controversy about what constitutes optimal zinc intakes in patients with type 2 diabetes mellitus. Several studies suggest that higher zinc intakes improve vascular function and decrease oxidative damage. We aimed to assess the effects of zinc supplementation using a range of reliable biomarkers of oxidative damage and vascular function in patients with type 2 diabetes. Methods: Forty male type 2 diabetic patients were supplemented either with 240mg/day of zinc as zinc gluconate (n=20) or with placebo (n=20) for 3 months. Blood and spot urine samples were taken at baseline, days 3 and 7, months 1, 2 and 3 during supplementation and 1 month after cessation. Serum zinc, reliable biomarkers of oxidative damage (F 2-isoprostanes, neuroprostanes, cholesterol oxidation products, allantoin) as well as hydroxyeicosatetraenoic acid products and vascular-related indices (augmentation index, pulse wave velocity and aortic pressure) were measured. Results: Despite significantly higher levels of serum zinc in the treatment group, markers of oxidative damage, levels of hydroxyeicosatetraenoic acid products and vascular indices were unchanged by zinc supplementation during the four-month study period. Conclusion: Improving the zinc status in patients with type 2 diabetes with normal zinc levels did not have any impact on oxidative damage and vascular function, and such supplementation may not be generally beneficial in these individuals. © 2011 Elsevier Ireland Ltd.en_HK
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosisen_HK
dc.relation.ispartofAtherosclerosisen_HK
dc.subjectOxidative damageen_HK
dc.subjectType 2 diabetesen_HK
dc.subjectVascular functionen_HK
dc.subjectZincen_HK
dc.subject.meshCholesterol - blood-
dc.subject.meshDiabetes Mellitus, Type 2 - blood - drug therapy - physiopathology-
dc.subject.meshDietary Supplements-
dc.subject.meshOxidative Stress - drug effects-
dc.subject.meshZinc - administration and dosage - blood-
dc.titleOral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levelsen_HK
dc.typeArticleen_HK
dc.identifier.emailLee, CYJ: jettylee@hku.hken_HK
dc.identifier.authorityLee, CYJ=rp01511en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.atherosclerosis.2011.07.097en_HK
dc.identifier.pmid21840002-
dc.identifier.scopuseid_2-s2.0-81155159707en_HK
dc.identifier.hkuros197983en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81155159707&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume219en_HK
dc.identifier.issue1en_HK
dc.identifier.spage231en_HK
dc.identifier.epage239en_HK
dc.identifier.eissn1879-1484-
dc.identifier.isiWOS:000296587200035-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridSeet, RCS=10045357300en_HK
dc.identifier.scopusauthoridLee, CYJ=13104265200en_HK
dc.identifier.scopusauthoridLim, ECH=8945547100en_HK
dc.identifier.scopusauthoridQuek, AML=13605538000en_HK
dc.identifier.scopusauthoridHuang, H=7405614576en_HK
dc.identifier.scopusauthoridHuang, SH=8367750600en_HK
dc.identifier.scopusauthoridLooi, WF=36523459100en_HK
dc.identifier.scopusauthoridLong, LH=7201908252en_HK
dc.identifier.scopusauthoridHalliwell, B=7101878919en_HK
dc.identifier.citeulike9620354-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats